Oramed Pharmaceuticals (ORMP) EBT Margin (2016 - 2025)

Oramed Pharmaceuticals' (ORMP) quarterly EBT Margin came in at 352.9% in Q1 2025, down 81.15% on a QoQ basis from 194.81% in Q2 2023.

Oramed Pharmaceuticals (ORMP) EBT Margin (2016 - 2025) Analysis & Trends

Oramed Pharmaceuticals (ORMP) has 8 years of EBT Margin data on file, last reported at 352.9% in Q1 2025.

Quarterly EBT Margin changed N/A year-over-year to 352.9% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 3766.2% (changed N/A YoY) and the FY2025 annual result came in at 3766.2%, changed N/A from the prior year.
EBT Margin fell to 352.9% in Q1 2025, from 194.81% in the prior quarter.
In the past five years, EBT Margin ranged from a high of 194.81% in Q2 2023 to a low of 1795.7% in Q2 2022.
A 4-year average of 986.45% and a median of 949.66% in 2021 frame the typical range for EBT Margin.
The widest YoY moves for EBT Margin: up 160089 bps in 2023, down 120586 bps in 2023.
Tracing ORMP's EBT Margin over 4 years: stood at 850.5% in 2021, then plunged by 59 bps to 1355.64% in 2022, then surged by 86 bps to 194.81% in 2023, then sank by 81 bps to 352.9% in 2025.
The last three EBT Margin figures came in at 352.9% (Q1 2025), 194.81% (Q2 2023), and 543.69% (Q1 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	35.61%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	35.71%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	13.77%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-2.67%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-25.06%
10	Oramed Pharmaceuticals	196.17 Mn	196.17 Mn	-	-

Download Data